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A B S T R A C T
Purpose
Treatment and prognosis of pediatric non-Hodgkin lymphoma (NHL) have improved dramatically in
the last 30 years. However, the St Jude NHL staging classification for pediatric NHL was
developed more than 35 years ago. The most recent Lugano lymphoma staging classification
focused on adult lymphoma. Furthermore, major limitations of the current pediatric NHL staging
classification include lack of consideration of new distinct pediatric NHL histologic entities;
absence of recognition of frequent skin, bone, kidney, ovarian, and other organ involvement; and
lack of newer precise methods to detect bone marrow and CNS involvement, minimal disease
quantification, and highly sensitive imaging technologies.
Methods
An international multidisciplinary expert panel convened in Frankfurt, Germany, in 2009 at the Third
International Childhood, Adolescent and Young Adult NHL Symposium to develop a revised
international pediatric NHL staging system (IPNHLSS), addressing limitations of the current
pediatric NHL staging system and creating a revised classification. Evidence-based disease
distribution and behavior were reviewed from multiple pediatric cooperative group NHL studies.
Results
A revised IPNHLSS was developed incorporating new histologic entities, extranodal dissemina-
tion, improved diagnostic methods, and advanced imaging technology.
Conclusion
This revised IPNHLSS will facilitate more precise staging for children and adolescents with NHL
and facilitate comparisons of efficacy across different treatment strategies, various institutions,
multicenter trials, and cooperative groups by allowing for reproducible pediatric-based staging at
diagnosis and relapse.
J Clin Oncol 33:2112-2118. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Dramatic improvements have occurred over the
past 35 years in childhood and adolescent non-
Hodgkin lymphoma (NHL) prognosis.1-14 Cur-
rently, localized or limited stage NHL (stage I to II)
has an approximate 95% to 100% 5-year event-free
survival (EFS) rate. Furthermore, the prognosis for
children with advanced-stage disease (stage III to
IV)has doubled froma5-yearEFSof approximately
40% 30 years ago tomore than 80%.1-7,10-14
The original St Jude childhood and adoles-
cent NHL staging system from 1980 is still used
today.15 However, over the last 35 years, there has
been a significant increase in identification of new
pathologic entities; improvements in cytogenetic,
molecular, and immunophenotypic characteriza-
tions of disease; new diagnostic methods for the
detection of minimal disseminated (MDD) or re-
sidual disease (MRD); and major advances in im-
aging applicable to childhood and adolescent
NHL. Furthermore, different pediatric cancer co-
operative groups and academic institutions have
developed and used different risk stratifications
incorporating clinical staging.1-4,7,11,13-16
Limitations of Current Pediatric NHL
Staging System
The St Jude staging system is primarily based
on clinicopathologic features of childhood Burkitt’s
lymphoma (BL) and lymphoblastic lymphoma
(LL).15 Stage is determined by the number and ana-
tomic pattern of disease sites, their resectability, and
involvement of marrow and the CNS.15 Since the
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introductionof theSt Judestagingsystem, thepathologicclassification
ofNHLhas changed significantly, andnew subtypes of pediatricNHL
have been identified, some of which display unique patterns of organ
involvement, includingmucosal sites, skin, bone, ovary, and kidney.
Limitations of Ann Arbor and More Recent
Lugano Classification
The original Ann Arbor staging system reported by Lister et al17
was designed without input from the pediatric oncology community
anddidnot reference specificpediatricNHLdisease entities or clinical
patterns. Similarly, the most recent update, the Lugano classification,
recently reported by Cheson et al,18 was developed without input
from the pediatric oncology community and does not reference
specific pediatric NHL disease entities.
METHODS
An international (North America, Europe, and Australia) subcommittee of
multidisciplinaryexperts (pediatriconcology,hematopathology, imaging, and
biology) in childhood and adolescentNHLwas convened to develop a revised
staging classification. Disease distribution and behavior of specific pediatric
NHL histologic subtypes frommultiple pediatric NHL trials fromfive pediat-
ric cooperative groups over the last 30 years were reviewed. New pathologic
entities, methods of minimal disease detection, and advances in imaging and
disease extent in pediatricNHLwere also reviewed. At theThird International
SymposiumonChildhood, Adolescent and YoungAdult NHLheld in Frank-
furt, Germany, in 2009, a revised St Jude childhood and adolescent staging
classificationwas presented to the international community of investigators of
childhood and adolescent NHL that incorporated evidence-based disease
spread and behavior derived from multiple studies of pediatric cooperative
groups.1-14 The final version was approved at the Fourth International Child-
hood, Adolescent and Young Adult NHL Symposium in New York, New
York, in 2012. Our report presents this proposed revised staging classification
of childhood and adolescent NHL, representing a multidisciplinary interna-
tional collaboration of experts in childhood and adolescent NHL.
RESULTS
Pathologic Classification
A pathologic diagnosis of NHL is dependent on identification of
specific morphologic features in combination with immunopheno-
type that can be determined by immunohistochemical staining of
paraffin-embedded fixed tissue or flow cytometric analysis of fresh
tumor cells,19-25 allowing for assignment of specific lymphoid lineage
(ie, T cell, B cell, or natural killer cell) and identifying patterns associ-
ated with cellular differentiation state or cell of origin.19-25
MDD Detection at Diagnosis
Identification of new disease-specificmarkers and recent techni-
cal advances have increased our ability to detect MDD with high
sensitivity and specificity.22-29 Molecular assessment of disease extent
may contribute to a renewed definition of disease stage in which
macroscopic,microscopic, andmolecular features are integrated.This
integrated approachmay also have consequences on risk stratification
of patients within the same subtype of NHL.26-28,30
BL. Since the early use of specific MYC-IGH gene rearrange-
ments as markers in BL, it has become evident that molecular tech-
niques, such as long-distance polymerase chain reaction (PCR), could
be used to complement diagnosis and determine marrow or blood
involvement.22,29,31 Recently, the analysis of idiotypic immunoglobu-
linH rearrangements has be used to detectMDD in the greatmajority
of patients with B-cell NHL (BL and diffuse large B-cell lymphoma),
with a sensitivity in the range of 0.01% to 0.001%.25 Moreover, pa-
tients with high-risk BL with minimal disease involvement of the
marrow at diagnosis had a significantly worse prognosis than patients
withMDD-negative BL (Fig 1).30
LL. The immunophenotype and genetic abnormalities of LL
cells are similar to those of acute lymphoblastic leukemia cells. The
sensitive and specific methodologies used for MRD monitoring in
acute lymphoblastic leukemia—including PCR amplification of spe-
cific genetic abnormalities and clonal immunoglobulin or T-cell re-
ceptor gene rearrangements and flow cytometric analysis with a
combination of LL blast specific markers—can be used to detect
submicroscopic disseminated disease in either blood or marrow in
LL, with a sensitivity of 0.01% and high specificity (Fig 2).26,32-34
Anaplastic large-cell lymphoma. The nucleophosmin anaplastic
lymphoma kinase (ALK) fusion gene (NPM-ALK) from the t(2;
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Fig 1. Survival analysis. Progression-free survival (PFS) analysis (A) in
patients with Burkitt’s lymphoma at high risk (Berlin-Frankfurt-Munster high-
risk group R4) according to morphologic bone marrow (BM) status at
diagnosis and (B) according to minimal disseminated disease (MDD) status in
BM at diagnosis. Data adapted.30
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5)(p23;q35) chromosomal translocation can be found in more than
90% of pediatric cases of anaplastic large-cell lymphoma (ALCL) and
can be used as a molecular disease marker, detectable by PCR or
immunohistochemistry forALKprotein overexpression.27,35,36 Avail-
ability of anti-ALK antibody has also significantly increased the ability
to detect low levels of ALCL tumor cells infiltrating the marrow that
could not be identified by morphologic examination of marrow
smears or trephines. PCR-based assays have allowed assessment of the
negative prognostic role of MDD at diagnosis in ALCL (Fig 3),24,27,37
as has flow cytometric analysis ofmarrow and blood using anti-ALK–
specific antibodies.37
Advances in Diagnostic Imaging
Contrast-enhanced computed tomography (CT) has served as
the main imaging modality for defining the burden and extent of
pediatric NHL since the St Jude staging system was introduced.15
Magnetic resonance imaging (MRI) has been used in staging of pedi-
atric NHL as an alternative to CT for patients with contraindications
to iodinated contrast and as a preferred method to evaluate primary
skeletal or CNS involvement. A reappraisal of the role of diagnostic
imaging in staging of pediatric NHL is warranted in view of advances
in CT and MRI technology, availability of [18F]fluorodeoxyglucose
(FDG) –positron emission tomography (PET), development of com-
bined PET-CT and PET-MRI scanners, and characterization of the
relative diagnostic efficacy of these imaging modalities. Newer appli-
cations, suchasperfusionCTandspectralCT,permit characterization
of tumor properties beyond just size and enable the transition of CT
fromapurelymorphologic to a functional imaging technique.38 Also,
new MRI techniques, such as perfusion MRI, diffusion-weighted
MRI,magnetic resonanceelastography, andmagnetic resonance spec-
troscopy, permit investigation of tumor metabolism and function
rather than justmorphology.39More recently, Klenk et al40 compared
whole-body diffusion MRI with ferumoxytol-T1–weighted images
with FDG-PET–CT in children and young adults with cancer. Un-
fortunately in this study, only five patients with NHLwere studied,
and none were age younger than 8 years. Ferumoxytol, an iron-
containing compound, is not currently approved in children, and
the serious adverse events related to this iron compound in chil-
dren are currently unknown.
The coregistrationof FDG-PETandCTorMRI images provided
by combined PET-CT and PET-MRI scanners allows more precise
correlation of radiopharmaceutical uptake with anatomic sites, per-
mitting better differentiation between physiologic and tumor uptake
andmore accurate tumor localization.Tumor cells that hyperconcen-
trate the glucose analog FDGbecause of increased glucose transporter
activity and glycolysis are detectable by FDG-PET imaging. Increased
FDG uptake is exhibited by more than 97% of sites of the aggressive
high-grade forms of NHL typically encountered in the pediatric pop-
ulation and in 80% to 90% of sites of more rare, indolent forms of
NHL, such as follicular lymphoma and extranodal marginal-zone
B-cell lymphoma of mucosa-associated lymphoid tissue.41,42 The
more recent report by Barrington et al43 revising the staging and
response criteria by PET-CT and the proposed 5-point scale to grade
response was entirely focused on adult diffuse large B-cell lymphoma
and follicular lymphoma histologies, with no reference to pediatric
NHL disease entities.
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Fig 2. Event-free survival according to levels of T-cell lymphoblastic lym-
phoma (T-LL) cells in bone marrow at diagnosis measured by flow cytometry.
Data adapted.26
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Fig 3. Outcome of patients with anaplastic large-cell lymphoma according to
quantitative polymerase chain reaction (PCR) results for NPM-ALK in bone
marrow. (A) Cumulative incidence of relapse and (B) Kaplan-Meier estimates of
event-free survival of 74 patients with either negative qualitative bone marrow
(BM) PCR or positive qualitative BM PCR using quantitative (quant) PCR results
and NPM-ALK cutoff copy number of 10 of 104 copies of ABL (normalized copy
number). NR, nonrelapse. Data adapted.27
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New Proposed International Pediatric NHL
Staging System
The St Jude staging system has been an invaluable tool to define
disease extent in pediatric NHL (Table 1).15 Our proposed revised
international staging system includes modifications in stage defini-
tions and the inclusion of new information, such as additional staging
information, to incorporate recentmedical progress (Tables 2 and 3).
Stage I. Because different pathologic types of NHL, including
those most recently defined by the WHO,20 present with different
localization patterns in terms of both region and tissue involved, we
have defined in detail specific sites of involvement, particularly with
reference to nodal versus extranodal sites, specifying for the latter skin
or bone involvement (Table 2). This is of special importance for
selected NHL subtypes, including ALCL, which more frequently
may arise with isolated localization to skin or with skin involve-
ment together with dissemination of disease to lymph nodes and
extranodal sites. Knowledge of whether extranodal localizations
relate to bone lesions may also be relevant, because localized bone
diseasemay have a better prognosis than other disease sites, at least
in some NHL subtypes.44
Stage II. In the proposed revised international pediatric NHL
staging system (IPNHLSS),multiple organ involvement is considered
stage III, irrespective of localization in relation to the diaphragm
(Table 2). In addition, selected limited abdominal involvement, such
as ileocecal involvement with or without adjacent mesenteric node
involvement (that is completely resectable), is considered stage II.
When there is concomitantmalignant ascites or the tumor extends to
different adjacent organs, the international and multidisciplinary ex-
pert panel was concordant in considering those conditions as nonlo-
calized disease. Thus, they should be regarded as stage III to
differentiate them from the true localized abdominal NHL. Some of
the specificationsoriginally includedas footnotes to theSt Judestaging
system15 were incorporated into the new IPNHLSS, with the aim of
keeping the definition of stage II as clear as possible. Some specifica-
tions on stage II previously included in the St Jude staging definition
were therefore eliminated (Tables 1 and 2).
Stage III. The considerations related to definition of stage II
disease also affect the definition of stage IIINHL. In particular, two or
more extranodal tumor localizations should be considered stage III,
independent of their localization in relation to the diaphragm. In
addition, tumor localization, including lymph nodes, skin, bone,
ovary, and kidney, should be explicitly specified (Table 2). Definition
of intrathoracic tumor was clarified to include hilar and pulmonary
localizations of disease in addition tomediastinal, pleural, and thymic
sites. For abdominal and retroperitoneal localizations, except for ileo-
cecal disease (with or without local lymph node involvement) that is
completely resected, any other disease in the abdomen should be
considered stage III. Explicitmention of liver, spleen, kidney, or ovar-
ian localization ofNHLhas also been introduced into this new system
formore specific clarification. Also, a single bone lesion together with
nonregionalnodalor extranodaldisease shouldbeconsidered stage III
disease. Paraspinal or epidural tumors are also defined as stage III
disease, independent of whether other sites are involved. This was
Table 1. Murphy Staging System
Murphy Staging System
Stage I
Single tumor (extranodal) or single anatomical area (nodal), with
exclusion of mediastinum or abdomen
Stage II
Single tumor (extranodal) with regional node involvement
 Two nodal areas on same side of diaphragm
Two single (extranodal) tumors  regional node involvement on same
side of diaphragm
Primary GI tract tumor, usually in ileocecal area,  involvement of
associated mesenteric nodes only
Stage III
Two single tumors (extranodal) on opposite sides of diaphragm
 Two nodal areas above and below diaphragm
All primary intrathoracic tumor (mediastinal, pleural, thymic)
All extensive primary intra-abdominal disease
All paraspinal or epidural tumors, regardless of other tumor sites
Stage IV
Any of above with initial involvement of CNS and/or bone marrow
involvement†
NOTE. Data adapted.15
Distinction is made between apparently localized GI tract lymphoma versus
more extensive intra-abdominal disease because of their quite different
patterns of survival after appropriate therapy. Stage II disease is typically
limited to segment of gut  associated mesenteric nodes only, and primary
tumor can be completely removed grossly by segmental excision. Stage III
disease typically exhibits spread via lymphatics to para-aortic and retroper-
itoneal nodes via intra-peritoneal dissemination to form implants and
plaques along mesentery or peritoneum or by direct infiltration of structures
adjacent to primary tumor. Ascites may be present, and complete resection
of all gross tumor is not possible.
†If marrow involvement is present initially, No. of abnormal cells must be
 25% in otherwise normal marrow aspirate with normal peripheral
blood picture.
Table 2. International Pediatric Non-Hodgkin Lymphoma Staging System
International Pediatric Non-Hodgkin Lymphoma Staging System
Stage I
Single tumor with exclusion of mediastinum and abdomen (N; EN; B or
S: EN-B, EN-S)
Stage II
Single EN tumor with regional node involvement
 Two N areas on same side of diaphragm
Primary GI tract tumor (usually in ileocecal area),  involvement of
associated mesenteric nodes, that is completely resectable (if
malignant ascites or extension of tumor to adjacent organs, it should
be regarded as stage III)
Stage III
 Two EN tumors (including EN-B or EN-S) above and/or below
diaphragm
 Two N areas above and below diaphragm
Any intrathoracic tumor (mediastinal, hilar, pulmonary, pleural, or thymic)
Intra-abdominal and retroperitoneal disease, including liver, spleen,
kidney, and/or ovary localizations, regardless of degree of resection
(except primary GI tract tumor [usually in ileocecal region] 
involvement of associated mesenteric nodes that is completely
resectable)
Any paraspinal or epidural tumor, regardless of whether other sites are
involved
Single B lesion with concomitant involvement of EN and/or nonregional
N sites
Stage IV
Any of the above findings with initial involvement of CNS (stage IV
CNS), BM (stage IV BM), or both (stage IV combined) based on
conventional methods
NOTE. For each stage, type of examination and degree of BM and CNS
involvement should be specified. Based on classification proposed by
Murphy.15
Abbreviations: B, bone; BM, bone marrow; EN, extranodal; N, nodal; S, skin.
Revised Pediatric NHL Staging System
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addressed in the original version of the St Jude staging system; how-
ever, in thenew IPNHLSS, it has beenmore clearly specified (Table 2).
Stage IV. Stage IVpediatricNHLhashistorically beendefined as
marrow and/or CNS involvement; this definition has been refined in
the revised IPNHLSS. However, the past definition did not specify
which site conferred the feature of stage IV or whether there was
concomitant involvement of bothmarrow andCNS. Frompublished
data, it is evident that marrow and, even more importantly, CNS
disease have different prevalence in different selected NHL subtypes;
for example, CNS involvement is rare in ALCL.7,24,45 Moreover, CNS
involvement usually carries a more negative prognostic impact than
marrow involvement, and CNS positivity represents a significant risk
factor even inpediatricNHLsubtypes.4,46Directly linked todefinition
of stage IV are the methods used to detect marrow or CNS involve-
ment, given that byusing different technical approaches, theremaybe
remarkably different degrees of sensitivity. This may influence the
definition of stage IV and consequently the risk classification of pa-
tients, with obvious therapeutic and prognostic implications. To this
aim, additional staging information (Table 3) should be collected that
specifies features of marrow and CNS involvement, particularly re-
lated to sensitivity and methods of analysis used for their detection,
but we recommend defining as stage IV those with bone marrow
(BM) positivity bymorphology or CSF positivity bymorphology and
leaving patients with BMpositivity by cytogenic or fluorescent in situ
hybridization (FISH) analysis, by immunophenotypicmethods, or by
molecular techniques in the stages otherwise assigned (Table 3); the
same criteria apply toCSF. Thus, theremight be a patientwith stage II
(eg, extranodal Waldeyer ring) BM positivity and CSF negativity by
molecular techniques or another patientwith abdominal stage III BM
negativity by cytogenic or FISH analysis and BM positivity by molec-
ular techniques.
Additional Staging Information
Although morphologic examination of marrow smears and
morphologic examination of CSF are still routinely performed, use of
specific monoclonal antibodies and new techniques, including flow
cytometry and PCR, have added much in terms of specificity and
sensitivity to our ability to detect marrow and CNS involve-
ment.25,26,28,29,47 As discussed, this has clear implications on the defi-
nition of stage IV and, consequently, on therapeutic decisions.
Therefore, it would be necessary to gain information on the levels of
sensitivityandspecificitybywhich thepresenceofmalignantcellshave
been detected. To this aim, four categories corresponding to different
technical levels of sensitivity and/or specificity were identified. They
include BM morphology, immunohistochemical or flow cytometry
methods, cytogenetic or FISH analysis, andmolecularmethods (PCR
based; Table 3). However, to maintain continuity with the previous
staging system and avoid upstaging patients on the sole basis of more
sensitive techniques, we propose maintaining the definition of stage
IV based on standard morphologic identification of blasts or tumor
cells. These supplementary categories would be applied to the analysis
of marrow and CNS. For the latter, based on emerging evidence that
CNSinvolvementmayhavedifferent implicationsontheoverallman-
agement and prognosis of patients with NHL, depending on whether
CNS positivity is the result of the presence of CNS tumor mass,
neurologic deficits (ie, cranial nerve palsy), or presence of blasts in the
CSF, type of CNS involvement should be reported.
DISCUSSION
For full clinical use of a staging system, we need to identify the objec-
tivesof theclassificationand themethodologyand techniquesused for
staging. A staging system is most valuable when it guarantees repro-
ducibility over extended periods of time, is applicable to different
subtypes of the disease of interest, andhas relevance for prognosis and
treatment stratification.
Similar to the recent Lugano classification report updating the
adult lymphomaAnnArbor stagingclassification, revision is currently
needed for the pediatric NHL classification.18 Several pediatric cancer
Table 3. Additional Staging Information
Additional Staging Information
BM involvement
Stage IV disease, resulting from BM involvement, is currently defined by
morphologic evidence of  5% blasts or lymphoma cells by BM
aspiration; this applies to any histologic subtype and will be
maintained in IPNHLSS
For each stage, type and degree of BM involvement (by BM aspiration)
should be specified, using abbreviations below to identify
involvement:
BMm: BM positivity by morphology (specify % lymphoma cells)
BMi: BM positivity by immunophenotypic methods
(immunohistochemical or flow-cytometric analysis; specify %
lymphoma cells)
BMc: BM positivity by cytogenetic or FISH analysis (specify %
lymphoma cells)
BMmol: BM positivity by molecular techniques (PCR based; specify
level of involvement)
Same approach should be used for PB involvement (ie, PBm, PBi, PBc,
PBmol)
Definition of BM involvement should be obtained from analysis of
bilateral BM aspirates and BM biopsy
CNS involvement
CNS is considered involved in case of:
Any CNS tumor mass (identified by imaging techniques [ie, CT, MRI])
Cranial nerve palsy that cannot be explained by extradural lesions
Blasts morphologically identified in CSF
Condition that defines CNS positivity should be specified: CNS positive/
mass, CNS positive/palsy, CNS positive/blasts
CSF status: CSF positivity is based on morphologic evidence of
lymphoma cells
CSF should be considered positive when any No. of blasts is detected
CSF unknown (not performed, technical difficulties)
Similarly to BM, type of CSF involvement should be described
whenever possible
CSFm: CSF positivity by morphology (specify No. of blasts/L)
CSFi: CSF positivity by immunophenotype methods
(immunohistochemical or flow cytometric analysis; specify %
lymphoma cells)
CSFc: CSF positive by cytogenetic or FISH analysis (specify %
lymphoma cells)
CSFmol: CSF positivity by molecular techniques (PCR based; specify
level of involvement)
NOTE. Until sufficient data are available, PET should be used with caution for
staging, and PET results should be compared and discussed in light of other
more consolidated imaging approaches.
Abbreviations: BM, bone marrow; CT, computed tomography; FISH, fluores-
cent in situ hybridization; IPNHLSS, International Pediatric Non-Hodgkin Lym-
phoma Staging System; MRI, magnetic resonance imaging; PB, peripheral
blood; PBc, PB positivity by cytogenetic or FISH analysis; PBi, PB positivity by
immunophenotype methods; PBm, PB positivity by morphology; PBmol, PB
positivity by molecular techniques; PCR, polymerase chain reaction; PET,
positron emission tomography.
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staging systems have been revised over the last 20 years.48-50However,
other classifications, distinct from staging classification, can address
more accurately issues related to prognosis and therapy. This is the
case in risk groupsdeveloped forpediatricNHL,where variables other
thandisease localization anddistribution are accounted for, including
histologic subtype, lactate dehydrogenase level, and so on.
After careful evaluation and discussion of several aspects in-
volved in the definition of stage in pediatric and adolescent NHL,
agreement was reached in the international expert panel to maintain
the general structure of the St Jude staging system, while introducing
somemodifications andmore explicit indications on peculiar sites of
disease, keeping in mind common clinical practice in particular enti-
ties.15 Moreover, it was decided to keep the staging system clearly
distinct from risk categories, where staging is usually only one of the
determinants.15 Different subtypes of childhood and adolescentNHL
havediverse risk factors, and some risk factors exist only in the context
of specific treatment strategies. Keeping staging as independent as
possible from risk categories will eventually help compare diseases,
prognoses, and treatment outcomes in different settings.
Fromthebeginningof this project,we recognized that important
progress in understanding the biology ofNHLwould affect prognosis
and clinical management. However, technology to detect specific bi-
ologic features is often limited in accessibility, and the impactmay still
be influencedby therapy. For this reasonandbecause there is evidence
that specific disease characteristics, includingMDD,may have a rele-
vant influence on outcome, we introduced an additional staging in-
formation section, with the aim of encouraging clinicians and
researchers to collect information on selected items related tomarrow
and CNS involvement. Thus, technical advances would be incorpo-
rated into a more comprehensive definition of stage and serve as a
background for future studies based on available evidence. In specific
conditions, only standard parameters will be collected, and less up-
dated technologiesmay be used to define disease extent. This decision
maintains continuity with a 30-year-old staging classification but also
incorporates the most significant elements of the recent biologic and
technologic progress. However, we were cautious not to overestimate
thepotential of new technology, such asPET scanning, that is yet to be
fully validated for staging of childhood and adolescent NHL.
This revised staging system should achieve themain goals of any
staging system, but it will also guarantee sufficient flexibility for fur-
ther modification and future improvements. The primary aim of this
revision was to provide a template that allows for a clear definition of
disease extent for pediatric NHL, which can then be used in risk
stratification processes, in which prognostic groups will be defined as
extent of disease, but includes other biologic and pathologic features,
depending on the specific type of pediatric NHL.With future collab-
orative studies now focusing on each pediatric histologic subtype, the
precise validation of the new IPNHLSS will become more evident in
thenear future andwill allowus to incorporate into the staging system
new advances to improve the management and outcome of children
and adolescents with NHL on a global scale.
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